What the FDA labels say about taking them together
Carbamazepine and norethindrone
Norethindrone's FDA label of January 31, 2026 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name norethindrone. The norethindrone label: “This could result in unintended pregnancy or breakthrough bleeding. Examples include rifampin, barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, and griseofulvin. b.”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the norethindrone FDA label on DailyMed (effective January 31, 2026, Glenmark Pharmaceuticals Inc., USA).
What does the carbamazepine label say about norethindrone?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name norethindrone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the norethindrone label say about carbamazepine?
Norethindrone label, drug interactionsSome drugs or herbal products that may decrease the effectiveness of HCs include efavirenz, phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, rifabutin, rufinamide, aprepitant, and products containing St. John’s wort.
Nora Be label (Teva Pharmaceuticals, Inc., April 2, 2024), drug interactionsThis could result in unintended pregnancy or breakthrough bleeding. Examples include rifampin, barbiturates, phenylbutazone, phenytoin, carbamazepine, felbamate, oxcarbazepine, topiramate, and griseofulvin. b.
Source: FDA drug label (Nora Be, NDA017060), Teva Pharmaceuticals, Inc., effective April 2, 2024 (SPL set 426ac898-7745-4645-bf9b-bae319e260e8), via openFDA
Source: FDA drug label (Norethindrone), Glenmark Pharmaceuticals Inc., USA, effective January 31, 2026 (SPL set 0d2f8fea-3675-40d2-afd9-9fcb148dbd4b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Norethindrone | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Birth control |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $0.290 per tablet 5 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once